Gastrointestinal Adverse Reactions In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients who received semaglutide tablets than placebo: semaglutide tablets 14 mg once daily (41%), semaglutide tablets 7 mg once daily (32%) and placebo (21%), including severe reactions (semaglutide tablets 14 mg 2.0%, semaglutide tablets 7 mg 0.6%, placebo 0.3%)
That said, many patients find the abdomen or thigh most convenient for self-injection as they're easier to reach
SURMOUNT-4 demonstrated that continued treatment maintained these results
Jacob Trefethen: Yeah, yeah, yeah
We provide comprehensive support, including monitoring for potential side effects and offering client education to ensure safe and optimal results
If youre unsure about your prescription path, see whether prescription treatment is the right next step